RBC Capital raised the firm’s price target on Ideaya Biosciences (IDYA) to $41 from $38 and keeps an Outperform rating on the shares. Ideaya Biosciences presented data on eye and visual acuity preservation from daro in the neo-adjuvant setting, suggesting evidence of very impressive anti-tumor efficacy leading to meaningful survival benefits, eye preservation and visual benefits, increasing the likelihood that upcoming phase III trials will read out positively, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Promising Potential of IDEAYA Biosciences’ Darovasertib: Strong Efficacy and Safety in Uveal Melanoma Trials
- IDEAYA Biosciences Presents Promising Phase 2 Data
- IDEAYA Biosciences: Promising Phase 1/2 Trial Results and Strong Upside Potential Justify Buy Rating
- Ideaya Biosciences presents clinical data from OptimUM-09 trial
- Ideaya Biosciences reports overall survival data from darovasertib trial